JNJ vs DXCM
By Alex · Tickerpine
Johnson & Johnson vs DexCom, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | DXCM |
|---|---|---|
| Price | $285.75 | $83.33 |
| Market cap | $687.89B | $31.08B |
| P/E ratio | 43.4 | 32.8 |
| ROE | 20.02% | 37.67% |
| Profit margin | 16.20% | 19.42% |
| Revenue growth | 5.90% | 11.20% |
| Dividend yield | 1.88% | 0.00% |
| Beta | 0.20 | 1.44 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs DXCM in plain English
- JNJ is the bigger company — about 22.1× the market cap of DXCM.
- DXCM is cheaper on earnings (P/E 32.8 vs 43.4).
- DXCM earns a higher return on equity (38% vs 20%).
- DXCM is growing revenue faster (11% vs 6%).
- JNJ pays a dividend (1.88%) while the other effectively doesn't.
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
DXCM return calculator
See what $1,000 in DexCom, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.